Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599827 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30838721 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29540221 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| Hydrochloric Acid SCHEMBL30191407 | 0.99 | MDM2 (0.55) | MDM2MDM4TP53TLR2CASP3 | |
| Hydrochloric Acid SCHEMBL29397950 | 0.99 | MDM2 (0.55) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL26009043 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53TLR2CASP3 | |
| Hydrochloric Acid SCHEMBL25356791 | 0.91 | MDM4 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| Hydrochloric Acid SCHEMBL25356795 | 0.91 | MDM4 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL27232374 | 0.91 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL27228619 | 0.91 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MDM2 2085/4885MDM4 2066/4885TP53 285/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | MDM2 4404/4885MDM4 3892/4885TP53 1808/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM2 3730/4885MDM4 934/4885TP53 3426/4885 |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | MDM2 3592/4885MDM4 4709/4885TP53 2289/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MDM2 2451/4885MDM4 963/4885TP53 81/4885 |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MDM2 2085/4885MDM4 2066/4885TP53 285/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | MDM2 1260/4885MDM4 2380/4885TP53 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.